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Abstract: 36 
Objectives: Oral mucosal macrophages (Ms) determine immune responses; 37 
maintaining tolerance whilst retaining the capacity to activate defences against 38 
pathogens.  M responses are determined by two distinct subsets; pro-inflammatory 39 
M1- and anti-inflammatory/regulatory M2-Ms.  Tolerance induction is driven by M2 40 
Ms, whereas M1-like Ms predominate in inflammation, such as that exhibited in 41 
chronic Porphyromonas gingivalis (PG) periodontal infection.  M responses can be 42 
suppressed to benefit either the host or the pathogen.  Chronic stimulation by 43 
pathogen associated molecular patterns (PAMPs), such as LPS, is well established to 44 
induce tolerance.  The aim of this study was to investigate the P. gingivalis-driven 45 
induction of and responsiveness to the suppressive, anti-inflammatory cytokine, IL-10, 46 
by M subsets.   47 
Methods: M1- and M2-like Ms were generated in vitro from the THP-1 monocyte cell 48 
line by differentiation with PMA and Vitamin D3, respectively.  M subsets were 49 
stimulated by PG-LPS in the presence or absence of IL-10.   50 
Results: PG-LPS differentially induced IL-10 secretion and endogenous IL-10 activity 51 
in M1- and M2-like subsets.  In addition, these subsets exhibited differential sensitivity 52 
to IL-10-mediated suppression of TNF, where M2 Ms where sensitive to IL-10 and 53 
M1 Ms were refractory to suppression.  In addition, this differential responsiveness 54 
to IL-10 was independent of IL-10-binding and expression of the IL-10 receptor signal 55 
transducing subunit, IL-10R, but was in fact dependent on activation of STAT-3.   56 
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Conclusion: P.gingivalis selectively tolerises regulatory M2 Ms with little effect on 57 
pro-inflammatory M1 Ms; differential suppression facilitating immunopathology at the 58 
expense of immunity.   59 
 60 
Key words: Periodontitis, Macrophage, Inflammation, Endotoxin Tolerance, 61 
Interleukin-10. 62 
 63 
Introduction: 64 
Chronic periodontitis (CP) is a chronic relapsing-remitting inflammatory disease of 65 
periodontal tissues, cycling between bouts of inflammation and immune suppression, 66 
resulting in destruction of the periodontium and ultimately tooth loss.  CP results from 67 
persistent microbial challenge by dysbiotic biofilms in which Porphyromonas gingivalis 68 
(PG) is an important member, inducing host inflammatory responses (Ximenez-Fyvie 69 
et al., 2000; Ezzo & Cutler, 2003).  PG is an intracellular oral pathogen, which infects 70 
mucosal macrophages (Ms) (Cutler et al., 1993; Yilmaz et al., 2002).  Clearance of 71 
which would normally require cell mediated immune responses, however PG-72 
lipopolysaccharide (PG-LPS) induces immune-deviation towards non-clearing 73 
humoral responses, facilitating pathogen persistence (Pulendran et al., 2001).  PG-74 
LPS also exhibits low endotoxin activity and structural variation, hence differential 75 
utilisation of TLR2 and TLR4 (Darveau et al., 2004); thus, subverting both adaptive 76 
and innate immunity to survive in mucosal tissue.  Immunosuppression can drive this 77 
immune deviation.  PG-LPS suppresses M responses by inducing endotoxin 78 
tolerance (ET); where LPS pre-exposure rendered innate immune cells refractory to 79 
subsequent endotoxin challenge (Biswas & Lopez-Collazo, 2009).  ET may be 80 
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beneficial or harmful to both host and pathogen; suppressing harmful over-exuberant 81 
pro-inflammatory tissue-destructive responses in the host (Foster & Medzhitov, 2009), 82 
whereas, simultaneously favouring pathogen persistence by suppressing protective 83 
inflammatory responses.  Oral mucosal Ms are important to ET; their activation status 84 
determining whether the mucosal environment is beneficial to the host or pathogen.  85 
PG modulates host cell function to benefit its own survival (Yilmaz, 2008).  86 
Interestingly, PG weakly induces pro-inflammatory cytokines, favouring insufficient 87 
clearing responses, bacterial proliferation and persistence.  The cytokines produced 88 
to this expanded bacterial number contribute to localised tissue destruction 89 
characteristic of CP (Gemmell et al., 1997; Garlet, 2010). 90 
 91 
Ms densely populate oral mucosa, responding to PG by producing pro-inflammatory 92 
cytokines (TNF, IL-1, IL-1, IL-18, IL-6, IL-12, IL-8, CCL2, CXCL10, MCP-1, IL-32) 93 
and lower anti-inflammatory cytokine levels (IL-10, TGF)(Zhou et al., 2005; Barksby 94 
et al., 2009): a profile suggestive of the M1 pro-inflammatory M subset.  In contrast, 95 
Ms from non-infected homeostatic mucosal tissue, exhibit a cytokine phenotype 96 
resembling the anti-inflammatory/ regulatory M2 subset (TGF, IL-10 and low levels 97 
of pro-inflammatory cytokines) (Merry et al., 2012).  PG-LPS-stimulated M1 M 98 
cytokine profiles suggest M1 association with pro-inflammatory pathology, whereas 99 
M2 Ms display a profile associated with regulatory/homeoatatic conditions (Foey & 100 
Crean, 2013).  These differential M responses correspond to expression of TLR2, 101 
TLR4 and their co-receptor molecule, CD14, driving potent inflammatory responses.  102 
CD14high M1 Ms produce high level pro-inflammatory- and low level regulatory-103 
cytokines, which if uncontrolled, results in higher levels of inflammation and 104 
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periodontal disease (Tervonen et al., 2007). Conversely, CD14low M2 Ms predict a 105 
non-pathogenic, homeostatic mucosal effector phenotype (Smith et al., 2005).  Thus, 106 
mucosal M effector phenotype (inflammatory vs regulatory) may be controlled by 107 
regulation of TLR-mediated signals.   108 
 109 
Ms can be tolerised by several mechanisms, including down-regulation of pattern 110 
recognition receptors (PRRs), induction of pro-inflammatory cytokine antagonists, 111 
endogenous inhibitors of PRR-mediated signalling and suppressive cytokines (TGF, 112 
IL-10) (Biswas & Lopez-Collazo, 2009).  The relevance of ET in the pathology of CP 113 
is the subject of intense research efforts.  PG-LPS is predominantly recognised by 114 
TLR2, instead of TLR4.  In CP, TLR2+ and TLR4+ monocytes are recruited into gingival 115 
lamina propria however, diseased tissue was generally tolerised by down-regulation 116 
of TLR2, TLR4, TLR5 and MD-2.  Functionally, PG-LPS pre-treatment of monocytes 117 
suppressed subsequent stimulation of both pro-inflammatory (TNF, IL-1, IL-6, IL-8) 118 
and anti-inflammatory cytokines (IL-10) (Muthukuru et al., 2005).  PG-LPS tolerisation 119 
of Ms however, was more complex where cytokines were differentially suppressed, 120 
dependent on M subset (Foey & Crean, 2013). 121 
 122 
The anti-inflammatory cytokine, IL-10, suppresses Minflammatory responses (Moore 123 
et al., 2001) and may be an important mediator of ET.  The potential therapeutic value 124 
of IL-10, coupled with its limited success in clinical trials (Fedorak et al., 2000; Tilg et 125 
al., 2002), suggest the need to investigate its functionality and signalling in chronic 126 
inflammatory diseases such as CP.  IL-10 signals are transduced by an IL-10R and 127 
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IL-10Rreceptor complex preceding a signal cascade involving JAK1/TYK2 and 128 
STAT3 (Finbloom & Winestock, 1995).  Crucially, STAT3 is associated with IL-10 129 
expression (Benkhart et al., 2000; Staples et al., 2007), anti-inflammatory function, 130 
inhibition of M activation (Donnelly et al., 1999) and the M2 M subset.  STAT3 131 
conditional knockout in murine Ms, rendered Ms refractory to IL-10 and 132 
development of chronic enterocolitis (Riley at al., 1999; Takeda et al., 1999). 133 
 134 
Our previous observations demonstrated differential Msubset sensitivity to PG-LPS 135 
induced ET (Foey & Crean, 2013).  It is probable that this different responsiveness to 136 
tolerisation is, in part, reflected by a subset-specific sensitivity to IL-10 anti-137 
inflammatory/regulatory responses, as a consequence of differential IL-10 induction 138 
and signal transduction pathways. Thus, the aim of this study was to investigate the 139 
production of and responsiveness to the regulatory cytokine IL-10 in functionally 140 
disparate M subsets, relevant to mucosal M effector function in the context of      P. 141 
gingivalis infection and chronic periodontitis. 142 
 143 
Materials and methods: 144 
Monocyte and macrophage (M) culture 145 
The human monocytic cell line, THP-1, was obtained from ECACC (Salisbury, UK) 146 
and used between passages 7 and 25.  THP-1 cells were maintained in RPMI-1640 147 
medium supplemented with 10% v/v foetal calf serum, 2 mM L-glutamine,100 U/ml 148 
penicillin and 100 g/ml streptomycin (Lonza, Wokingham, UK), here on referred to as 149 
R10.  Cells were plated out at 1x105 cells/well in R10, in 96 well flat-bottomed tissue 150 
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culture plates.  Pro-inflammatory (M1-like) Ms and anti-inflammatory (M2-like) Ms 151 
were generated by THP-1 monocyte differentiation in the presence of 25 ng/ml PMA 152 
or 10 nM 1,25-(OH)2-Vitamin D3 (Sigma-Aldrich, Poole, UK) for 3 and 7 days, 153 
respectively (Daigneault et al., 2010).  PMA and Vitamin D3-differentiated Ms were 154 
phenotyped according to gene expression and compared favourably to the established 155 
phenotype of conventional M1 and M2 subsets:  PMA M1-like Ms were TNFhi, IL-156 
8hi, IL-12hi, iNOShi, IL-10lo, Arginaselo whereas Vitamin D3 M2-like Ms were TNFlo, 157 
IL-8lo, IL-10hi, Arginasehi, CD206hi. 158 
 159 
Bacteria and pathogen associated molecular patterns (PAMPs) 160 
Due to the ability of P.gingivalis to induce inflammatory factors via membrane 161 
receptors, the effects of P. gingivalis lipopolysaccharide (PG-LPS) were studied.  PG-162 
LPS was obtained from Autogen Bioclear, Calne, UK.  This PAMP was  extracted from 163 
P. gingivalis strain ATCC 33277 originally isolated from human gingival sulcus 164 
(American Type Culture Collection).    The suppliers extracted PG-LPS by successive 165 
enzymatic hydrolysis and purification by Phenol-TEA-DOC protocol (Hirschfeld et al., 166 
2000), prior to being made commercially available.   167 
 168 
Activation of monocyte and macrophage cytokine production 169 
THP-1-derived M1- and M2-like Ms were stimulated by the bacterial PAMP; 100 170 
ng/ml PG-LPS and cultured for 18 hours (determined as optimal concentration and 171 
time period for expression of the inflammatory cytokines TNF, and IL-10, data not 172 
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shown).  Supernatants were harvested and stored at -20oC until required for cytokine 173 
assay by sandwich ELISA. 174 
 175 
Induction of endogenous IL-10 activity and modulation of macrophage TNF 176 
production by exogenous IL-10 177 
Endogenous cell-associated IL-10 was assayed based on anti-inflammatory activity of 178 
IL-10 to suppress LPS-induced TNF.  M1and M2 Ms were pre-treated with 10 g/ml 179 
9D7 neutralising anti-IL-10 antibody (Biolegend, San Diego, USA) or irrelevant, 180 
isotype-matched control antibody for 30 minutes prior to stimulation with 100ng/ml PG-181 
LPS and cultured for 18 hours at 37oC, 5% CO2.  In addition, M sensitivity to 182 
exogenous IL-10 was assayed where M1 and M2s were pre-treated with exogenously 183 
added IL-10 (0, 0.2, 2 and 20 ng/ml)(NIBSC, Potter’s Bar, UK) for 30 minutes prior to 184 
stimulation with 100ng/ml PG-LPS and cultured for 18 hours. Supernatants were 185 
collected and assayed for TNF secretion by sandwich ELISA.  M viability was 186 
routinely checked by either MTT assay or trypan blue exclusion.  A physiologically-187 
relevant response was indicated, as no significant reductions in viability were observed 188 
for any treatments used in this study (viability routinely >85%). 189 
 190 
Cytokine measurement 191 
TNF and IL-10 were analysed by sandwich ELISA using commercially available 192 
capture and detection antibodies (BD-Pharmingen, Oxford, UK).  Protocols were 193 
followed according to manufacturer’s instructions and compared to standard curves 194 
(range of 7 to 5,000 pg/ml), using international standards available from NIBSC.  195 
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Colorimetric development was measured spectrophotometrically by an OPTIMax 196 
tuneable microplate reader at 450 nm and analysed by Softmax Pro version 2.4.1 197 
software (Molecular Devices Corp., Sunnyvale, CA, USA). 198 
 199 
Flow cytometric analysis of IL-10 binding and IL-10R 200 
IL-10 binding to the ligand-binding IL-10R chain was determined using Fluorokine 201 
Biotinylated human interleukin-10 (R&D Systems, Abingdon, UK) according to 202 
manufacturer’s instructions. Briefly, Ms were washed and resuspended to 1x105 cells 203 
per tube.  Biotinylated IL-10 was added to the cells and incubated on ice for 60 mins.  204 
Avidin-FITC was then added and incubated for 30 mins on ice.  Finally, cells were 205 
washed, resuspended in FACS buffer for analysis. Specificity of IL-10 binding was 206 
determined using anti-IL-10 blocking antibody added to biotinylated IL-10 prior to 207 
introduction to Ms.  Measurment of the IL-10 signalling chain (IL-10R) used a directly 208 
conjugated, PE-anti-IL-10R antibody according to manufacturer’s instructions. 209 
Briefly, Ms were washed and resuspended to 1x105 cells per tube.  PE-anti-IL-10R 210 
was added to the cells and incubated on ice for 60 mins.  Stained cells were washed, 211 
resuspended in FACS buffer and analysed using a BD FACS Aria II flow cytometer. 212 
Data collected represented net mean fluorescent intensities using a live gating 213 
strategy set for FSC/SSC.   214 
 215 
Western blot analysis of phospho-STAT3 216 
M1 and M2-like Ms were seeded in 12 well plates at 1x106 cells/ml.  Ms were pre-217 
treated with IL-10 or anti-IL-10 for 1 hour prior to stimulation with 100 ng/ml PG-LPS 218 
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for 30 mins (optimal stimulation for STAT3 activation).  Following stimulation, cells 219 
were lysed on ice for 15 min in lysis buffer (1% NP-40, 200 mM NaCl, 0.1mM 220 
ethylenediaminetetra-acetic acid, 1mM dithiothreitol, 1mM Na3VO4, 1mM NaF, 1mM 221 
phenylmethylsulphonyl fluoride, 10 g/ml leupeptin, 10 g/ml pepstatin and 10 g/ml 222 
aprotinin).  Lysed samples (10g) were separated on a 12% sodium dodecyl sulphate-223 
polyacrylamide gel and Western blotted onto PVDF membrane (Thermo Fisher 224 
Scientific, Cramlington, UK).  Phosphorylated STAT3 was detected using anti-225 
phosphoSTAT3 (Tyr 705) antibody (New England BioLabs Ltd., UK) followed by anti-226 
rabbit HRP conjugate (New England BioLabs Ltd., UK) and enhanced 227 
chemiluminescence (Amersham Pharmacia Biotech UK Ltd., Little Chalfont, UK).  228 
STAT3 total protein was detected for the purpose of loading controls to the 229 
corresponding phospho-Western.  Protein bands were scanned and visualised for 230 
chemiluminescence by a Typhoon Trio variable mode imager (GE Healthcare, UK). 231 
 232 
Statistical analysis 233 
Measure of statistical significance was analysed using a balanced analysis of variance 234 
(General Linear Model, Minitab version 16) followed by a multiple comparison test 235 
(LSD, least significant difference).  Significance was set at p<0.05 (*p<0.05, **p<0.01 236 
and ***p<0.001). 237 
 238 
 239 
 240 
 241 
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Results: 242 
PG-LPS differentially induces Msubset IL-10 production  243 
M1 and M2 Ms produce different cytokine profiles; M1s exhibit a predominantly pro-244 
inflammatory profile whereas M2s express a more anti-inflammatory/regulatory profile.  245 
This experiment was undertaken to establish whether M1 and M2 Ms respond 246 
differently with respect to induction of IL-10 in response to PG.  Indeed, PG-LPS 247 
induced distinct subset-specific cytokine profiles.  PG-LPS induced minimal secretion 248 
of IL-10 by M1-like Ms (secretion significant, p=0.0051, but close to lower level of 249 
sensitivity of ELISA), compared to M2 Ms (figure 1a).  M2-secreted IL-10 however, 250 
was measured at relatively low levels (120±10 pg/ml, p<0.0001). In addition to 251 
secretion, considering membrane bound IL-10 has been demonstrated (Fleming et al., 252 
1999), this endogenous activity was also investigated using neutralising anti-IL-10 253 
antibody in the context of TNFsuppression.  No endogenous activity was exhibited 254 
by unstimulated Ms (figure 1b & 1c).  Upon PG-LPS stimulation however, M subsets 255 
exhibited differential expression of endogenous IL-10 activity.  PG-LPS failed to induce 256 
an endogenous suppressive IL-10 activity in M1s; induction of TNFdid not exhibit a 257 
statistically significant change (p=0.247) between isotype-matched control and 258 
neutralising anti-IL-10 antibody (Figure 1b).  PG-LPS did, however, induce an 259 
endogenous IL-10 activity expressed by M2-like Ms.  Neutralisation of IL-10 activity 260 
augmented TNF secretion by 20% (p=0.011, figure 1c).  261 
 262 
[ADD FIGURE 1 HERE] 263 
 264 
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M1- and M2-like Ms differentially respond to IL-10 265 
Upon PG-LPS challenge, M subsets differentially produce secreted IL-10 and 266 
endogenous IL-10 activity.  The responsiveness of these Msubsets to the anti-267 
inflammatory cytokine, IL-10, was investigated by IL-10 ability to suppress TNF.  In 268 
the case of pro-inflammatory M1-like Ms, IL-10 failed to significantly suppress PG-269 
LPS-induced TNF secretion to a concentration of 20 ng/ml (figure 2).  In contrast, 270 
M2-like Ms were sensitive to the anti-inflammatory effects of IL-10; where IL-10 dose-271 
dependently suppressed PG-LPS-induced TNF by 75% at 20 ng/ml (p<0.01) (figure 272 
2).   273 
 [ADD FIGURE 2 HERE] 274 
 275 
M1- and M2-like Ms display similar IL-10 binding capability and signalling 276 
receptor, IL-10R expression 277 
This differential IL-10-sensitivity suggested different binding capabilities between M1- 278 
and M2-like Ms.  IL-10 binds the IL-10R -subunit; it was hypothesised that IL-10R, 279 
hence IL-10 binding capability varied between these subsets.  This was investigated 280 
by IL-10 ligand-binding, which demonstrated IL-10 binding was both unaltered by PG-281 
LPS stimulation or affected by M subset (figure 3a).  There was no significant 282 
difference in binding activity between unstimulated M1 and M2 Ms and that this 283 
binding activity was not significantly altered by PG-LPS for M1 (p=0.165) or M2 284 
(p=0.749) Ms. 285 
 286 
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In light of the differential IL-10-sensitivity exhibited by these M subsets, which failed 287 
to be reflected by IL-10-binding activity (IL-10R), a further investigation was 288 
undertaken to observe whether this responsiveness was as a consequence of IL-10R 289 
signal transducing subunit, IL-10R.  Both M1 and M2s expressed IL-10R in the 290 
absence of PG-LPS, with M2 Ms expressing greater levels of this receptor subunit 291 
(MFI = 2000 AU compared to 1000 AU for M1s)(figure 3b).  Upon PG-LPS stimulation 292 
however, both M1 and M2s exhibited significant down-regulation in IL-10R (M1s, 293 
p=0.0414 and M2s, p=0.0035). 294 
[ADD FIGURE 3 HERE] 295 
 296 
STAT-3 is differentially activated by PG-LPS and IL-10 in M1- and M2-like Ms 297 
Down-regulation of the receptor signalling subunit in both M1 and M2 Ms does not 298 
adequately explain differential responsiveness to IL-10.  Downstream of IL-10 receptor 299 
signalling, STAT3 mediates anti-inflammatory responses.  Thus, STAT-3 activation 300 
may determine this differential sensitivity to IL-10.  Phospho-Western blot analysis 301 
showed M1 Ms failed to activate STAT3 in response to PG-LPS in the presence or 302 
absence of IL-10.  IL-10 alone only superficially activated STAT3 (figure 4a).  In 303 
contrast, PG-LPS clearly activated STAT3 in M2 Ms, augmented by exogenous IL-304 
10.  The PG-LPS-induced phospho-STAT3 was dependent on endogenous IL-10; 305 
neutralisation of which abrogated STAT3 activation (figure 4b). 306 
[ADD FIGURE 4 HERE] 307 
 308 
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DISCUSSION: 309 
Previous studies from this laboratory have shown M1- and M2-like Ms to exhibit 310 
differential sensitivity to ET (Foey & Crean, 2013).  In an attempt to elucidate 311 
mechanisms underlying this differential sensitivity, this investigation has drawn several 312 
conclusions with respect to M responses to the oral pathogen, P. gingivalis.  Firstly, 313 
PG-LPS activation induces M subset-specific responses, where M2-like Ms 314 
preferentially secrete IL-10 as well as an endogenous cell-associated activity, 315 
compared to M1-like Ms.  Secondly, Ms also displayed a selective, subset-specific 316 
responsiveness to IL-10.  M1 Ms were refractory to the anti-inflammatory activity of 317 
IL-10 whereas M2s were sensitive.  Finally, differential IL-10 responsiveness was not 318 
as a consequence of selective expression of IL-10-binding activity (IL-10R) or signal 319 
transduction receptor (IL-10R), but reflected by activation of the downstream 320 
transcription factor, STAT3. 321 
 322 
The pathological role for Ms in chronic periodontitis is well established.  Indeed, M 323 
numbers have been shown to be increased above healthy control levels in CP gingival 324 
tissue biopsy samples (Gemmell et al., 2001; Lappin et al., 2000).  P.gingivalis, the 325 
keystone pathogen to periodontitis, drives the gingipain-mediated activation of the M 326 
urokinase plasminogen activator (uPA) system, resulting in a proteolytic cascade 327 
involved in inflammatory destruction and loss of bone architecture (Fleetwood et al., 328 
2015).  In addition, M depletion has been demonstrated to be associated with a 329 
reduction in inflammation and alveolar bone resorption, where the M1 subset 330 
predominates in response to P.gingivalis infection, resulting in an inflammatory 331 
phenotype defined by the increased secretion of TNF, IL-1, IL-6, IL-12p70, MCP-1 332 
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and MIP-1 (Lam et al., 2014).  The potential predominance of an M1-like subset in 333 
CP conforms to phenotypic observations of P.gingivalis stimulation of murine M 334 
studies, where both PG-LPS and P.gingivalis bacteria induced expression of TNF, 335 
IL-12 and iNOS by IFN-primed M1 Ms (Holden et al., 2014; Lam et al., 2016).  In 336 
this investigation, PG-LPS stimulation of human M1 and M2 M subsets demonstrated 337 
differing cytokine effector profiles; where M1s (representative of recruited, pro-338 
inflammatory pathological Ms) exhibited a pro-inflammatory phenotype (TNFhi, IL-339 
1lo, IL-6lo, NFkBhi,IL-10lo) and M2s (representative of regulatory, anti-inflammatory 340 
mucosal Ms) tended to be more anti-inflammatory/regulatory (TNFlo, IL-1hi, IL-6hi, 341 
NFkBlo, IL-10+, TGF+) (Foey & Crean, 2013; Holden et al., 2014).  Mucosal Ms are 342 
considered to exist in these discrete functional subsets, governed by environmental 343 
stimuli (Smythies et al., 2005; Foey, 2012). This investigation demonstrated IL-10 344 
production conforms to this functional subset dichotomy with respect to M2 Ms 345 
exhibiting higher levels of both secreted and endogenous cell-associated IL-10 when 346 
stimulated by PG-LPS.  Conversely, M1 Ms failed to display an endogenous IL-10 347 
activity and resulted in low level secretion. 348 
 349 
IL-10 regulates/suppresses pro-inflammatory responses (Fiorentino et al., 1991).  This 350 
anti-inflammatory effect can be elicited at many levels; including, down-regulating 351 
TNFsecretion, suppressing TNFactivity via inducing TNF-R shedding or by 352 
modulating NFB-signalling events driving TNF production (Schottelius et al., 1999).  353 
Although these M subsets have been characterised with respect to TNF and IL-10, 354 
the level of cross-regulation and plasticity exhibited by these subsets is highlighting 355 
the importance to characterise subset responsiveness to regulatory cytokines such as 356 
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IL-10.  Our data clearly establishes a differential responsiveness of M subsets to IL-357 
10, where M1s were refractory and M2s sensitive to the anti-inflammatory effects of 358 
IL-10.  This sensitivity of M2s to IL-10 suppression of TNF would appear to be 359 
independent of subset-specific binding activity and signal transduction receptor and is 360 
reflected by differential utilisation of downstream intracellular signalling pathways. 361 
 362 
The desired outcome would be to harness anti-inflammatory properties of IL-10; 363 
controlling inflammatory mechanisms in chronic diseases such as CP.  This data 364 
introduces two problems: 1) lack of Msubset selectivity of IL-10 binding and 2) the 365 
IL-10-responsive subset is the M2 regulatory subset whereas the M1 pro-inflammatory 366 
pathological subset is unresponsive.  This study may suggest why IL-10 treatment has 367 
exhibited limited success in suppressing M-driven chronic inflammatory diseases 368 
such as RA, CD and psoriasis (Fedorak et al., 2000; Tilg et al., 2002; McInnes et al., 369 
2001).  The specificity of IL-10-mediated anti-inflammatory response would appear to 370 
result from differential activation and utilisation of STAT3 (Benkhart et al., 2000).  PG-371 
LPS activates STAT3 in M2 Ms, this response is indirect through IL-10; neutralisation 372 
of which abrogated the activation response.  Due to the short activation time used in 373 
this experiment (30 mins), the IL-10-dependency does not result from de novo IL-10 374 
synthesis but is likely to result from a pre-existing endogenous IL-10 activity observed 375 
for M2s.  Interestingly, PG-LPS stimulation in the presence of exogenous IL-10 376 
dramatically augmented STAT3 activation.  Coupled with the fact that results showed 377 
a PG-LPS-induced decrease in IL-10R and no change for IL-10R, the PG-LPS 378 
augmentation of STAT3 activation would appear to be both IL-10-dependent in early 379 
responses and IL-10-independent at later times. 380 
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 381 
IL-10 and STAT3 are not only directly involved in anti-inflammatory and regulatory 382 
responses but indirectly via effects on M polarisation.  Both IL-10 and STAT3 383 
influence M plasticity and differentiation towards the M2 effector subset.  Conditional 384 
knock-out of M STAT3, renders mice refractory to IL-10 and develop chronic 385 
enterocholitis (Riley et al., 1999; Takeda et al., 1999); although STAT3 is necessary 386 
for IL-10 signalling, additional pathways are required for M inhibition.  One such 387 
mechanism may involve IL-10-inducible STAT3-regulated gene expression of SOCS3, 388 
which negatively feeds-back to regulate IL-10 signalling (Donnelly et al., 1999; 389 
Cassatella et al., 1999; Auernhammer et al., 1999).  SOCS3 may not just regulate anti-390 
inflammatory responses but also M2 to M1 switch, driving M plasticity towards this 391 
pro-inflammatory phenotype (Liu et al., 2008).  Manipulation of M effector phenotype 392 
via controlling plasticity between M1 and M2 subsets, or specific M subset tolerance 393 
induction, hence determining immune response as either pro-inflammatory/immune 394 
activatory or anti-inflammatory/tolerogenic, would greatly benefit therapeutic 395 
management of inflammatory pathologies such as CP.  396 
 397 
Intuitively CP, a relapsing/remitting chronic inflammatory disease, is constantly 398 
switching between inflammation and tolerance: inflammation targets the pathogen and 399 
results in collateral damage of host tissue whereas ET results in tissue repair and a 400 
chance for pathogen numbers to recover.  This differential Msensitivity to the anti-401 
inflammatory effects of IL-10 however, is suggestive of a disease stage whereby 402 
homeostatic M2-like Ms are suppressed by IL-10 whereas the pro-inflammatory 403 
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nature of M1 Ms is untouched.  Such a differential suppression may be beneficial for 404 
controlling pathogen numbers but will be detrimental to tissue repair. 405 
 406 
In conclusion, this investigation further characterises M1- and M2-like M subsets with 407 
respect to PG-LPS-induced activation/suppression decisions.  Selective M subset 408 
tolerisation and responsiveness to anti-inflammatory cytokines affords us a better 409 
understanding of the role of distinct M subsets in driving both activatory and 410 
suppressive stages in CP.  Investigation of subset sensitivity to IL-10-mediated 411 
suppression observed that the subset least sensitive to IL-10 suppression was the pro-412 
inflammatory pathological subset, M1.  This would suggest that such mechanisms of 413 
ET may be detrimental to the host tissue and its repair.  Selective manipulation of M 414 
subset suppression, hence the balance of activation and suppression between such 415 
subsets, may represent a translatable future therapeutic approach for the control of 416 
such destructive oral inflammatory pathologies but can only realistically be employed 417 
upon full understanding of the mechanisms driving such relapsing/remitting episodes 418 
characteristic of CP. 419 
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 556 
Figure legends: 557 
Figure 1.  M1 & M2 Ms display differential IL-10 profiles in response to PG-LPS. 558 
THP-1-derived M1 and M2 Ms were generated by differentiating THP-1 monocytes 559 
with either 25ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10nM 1,25-560 
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(OH)2 vitamin D3 for 7 days, respectively.  Secretion of IL-10 (a) is depicted where M1 561 
(bold) and M2 (shaded) M subsets were stimulated with or without (control) 100ng/ml 562 
PG-LPS.  Endogenous IL-10 activity, upon treatment with 10g/ml neutralising anti-IL-563 
10 compared to an isotype-matched control antibody (IC), is represented for PG-LPS-564 
stimulated and unstimulated M1 (b) and M2 (c) macrophage TNF secretion.  Cytokine 565 
production is expressed as the mean±SD in pg/ml for IL-10 (a) and TNF (b & c).  Data 566 
displayed represents triplicate samples for n=3 replicate experiments.  Significant 567 
differences in cytokine production between activated M1 and M2 Ms and 568 
unstimulated controls and between isotype control and neutralising IL-10 antibody 569 
treatment are indicated as *p<0.05, **p<0.01, ***P<0.001 and ns, not significant. 570 
 571 
Figure 2.  Differential sensitivity of PG-LPS-induced M TNF to IL-10.  M1 (bold) 572 
and M2 (shaded) M subsets were stimulated with 100ng/ml PG-LPS for 24hours in 573 
the presence or absence of IL-10 at concentration range from 0 to 20ng/ml.  Anti-574 
inflammatory effect of IL-10 on TNF cytokine production is expressed as percentage 575 
of LPS-induced TNF production originally represented as mean±SD in pg/ml.  Data 576 
displayed represents triplicate samples for n=3 replicate experiments.  Significant 577 
effects compared to PG-LPS control in the absence of IL-10 (0ng/ml) is indicated for 578 
M subsets as **p<0.01 and ns, not significant. 579 
 580 
Figure 3.  M1 and M2 Ms exhibit similar IL10R subunit expression in response 581 
to PG-LPS.  THP-1-derived M1 and M2 Ms were generated by differentiating THP-1 582 
monocytes with either 25ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 583 
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10nM 1,25-(OH)2 vitamin D3 for 7 days, respectively.  FITC-labelled IL-10 binding to 584 
the IL-10R ligand-binding subunit (a) and anti-IL-10R antibody binding of the 585 
signalling subunit (b) is depicted in net MFI±SD for M1 and M2 Ms in the presence 586 
or absence of PG-LPS (100 ng/ml) stimulation.  Data displayed represents triplicate 587 
samples for n=3 replicate experiments.  Significant differences in binding activity 588 
between PG-LPS stimulated and non-stimulated Mcontrols are indicated as *p<0.05, 589 
**p<0.01 and ns, not significant. 590 
 591 
Figure 4.  STAT3 is differentially activated by PG-LPS and IL-10 in M1 and M2 592 
Ms.  THP-1-derived M1 and M2 Ms were plated out at 5x106 cells per well in a flat-593 
bottomed 12 well plate and treated with PG-LPS (100 ng/ml) in the presence or 594 
absence of exogenously added IL-10 (10ng/ml) or neutralising anti-IL-10 antibody 595 
(10g/ml 9D7).  After 30 mins stimulation time, cell lysates were harvested.  Western 596 
blot analysis of activated phospho-STAT3 shows IL-10-mediated activation of STAT3 597 
in M1 (a) and M2 (b) Ms.  Loading controls are presented as total STAT3 blots below 598 
the corresponding phospho-Westerns.  Data displayed are representative of three 599 
replicate experiments.   600 
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